Zepbound vs Wegovy: What's Actually Different

Most comparisons of these two stop at one sentence: Zepbound produces more weight loss. That is true, and it is the least useful thing to know, because it is rarely the part that decides which one you can actually get.

The short version

Comparing the diabetes-branded versions of the same two molecules instead? That is Mounjaro vs Ozempic — same drugs, different labels, and neither is approved for weight management.

Zepbound is tirzepatide. It acts on two gut-hormone receptors (GIP and GLP-1). Wegovy is semaglutide 2.4 mg. It acts on one (GLP-1). Both are FDA-approved for chronic weight management, both are once-weekly injections, and both carry the same boxed warning about thyroid C-cell tumours.

In the only head-to-head trial, tirzepatide produced more weight loss. But the two drugs carry different additional FDA indications, and for a lot of people that difference — not the six percentage points — determines which one a prescriber chooses and which one insurance will pay for.

Results: the one head-to-head we have

Most comparisons splice together separate trials, which is unreliable because the populations differ. There is now one direct comparison: SURMOUNT-5, published in the New England Journal of Medicine, which randomised adults with obesity and without type 2 diabetes to the maximum tolerated dose of either drug for 72 weeks.

At 72 weeks	Tirzepatide	Semaglutide
Average weight reduction	20.2%	13.7%
Lost ≥10% of body weight	81.6%	60.5%

The estimated treatment difference was −6.5 percentage points (95% CI −8.1 to −4.9, p<0.001). Tirzepatide also produced a greater reduction in waist circumference.

Two caveats worth holding onto. These are trial averages, and individual response varies widely in both arms — plenty of people on semaglutide lost more than the tirzepatide average. And the trial excluded people with type 2 diabetes, so it does not describe that group.

The indications are the real difference

This is the part most comparisons skip, and it is often what actually decides things.

Wegovy has a cardiovascular indication. In March 2024 the FDA approved it to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. That was based on the SELECT trial, where the primary composite outcome occurred in 6.5% on semaglutide versus 8.0% on placebo — roughly a 20% relative risk reduction, or about 1.5 percentage points in absolute terms over a mean 40 months.

Zepbound has a sleep-apnea indication. In December 2024 it became the first prescription medicine approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

Why this matters more than it sounds: insurance decisions often follow indications. If you have established cardiovascular disease, there is an approved indication pointing at Wegovy that does not exist for Zepbound. If you have diagnosed moderate-to-severe OSA, the reverse is true. Having a documented condition that matches an approved indication is frequently the difference between a prior authorisation being approved and denied — which is a far bigger practical gap than six percentage points of average weight loss.

Neither of these is something to self-diagnose toward. They are things to raise with your prescriber if they already apply to you.

Side effects: more alike than different

Both are dominated by gastrointestinal effects — nausea, vomiting, diarrhoea, constipation, abdominal pain. In SURMOUNT-5 the safety profiles were broadly consistent with what each drug had shown before, and GI effects were the most common reason people stopped in both groups.

Both labels carry the same boxed warning for thyroid C-cell tumours, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both list pancreatitis, gallbladder disease, and kidney injury from dehydration among the warnings.

In practice, the deciding factor is usually individual tolerability rather than the drug’s profile — some people tolerate one and not the other, and that is not predictable in advance.

Dosing and practicalities

Both are once-weekly self-injections titrated upward over months, which is deliberate: escalating slowly is how the GI effects are managed. Expect the first several months to be dose escalation rather than a maintenance dose.

That has a cost consequence people rarely plan for. Some providers price by dose, so your monthly cost can rise as your dose does — which means the number quoted at signup may not be the number you pay in month four. Our real cost guide covers how to check that before enrolling.

Cost: usually the real decider

With insurance coverage, whichever one your plan covers is usually the answer, and that is increasingly driven by the indication match described above.

Without insurance, both manufacturers now run self-pay channels, and telehealth platforms resell them. As of our September 2026 price check, self-pay Wegovy typically starts lower than self-pay Zepbound — commonly around $199/month for the Wegovy pen against roughly $299/month for Zepbound, with oral semaglutide options appearing around $149/month. Membership fees are usually charged on top of those figures.

So the honest cost framing is: the drug that performs better in trials is also usually the more expensive one. Whether roughly $100/month of difference is worth roughly six percentage points of average weight loss is a real question with no universal answer, and it depends on how long you expect to be treated. Our all-in cost calculator will do the 12-month arithmetic.

How to actually decide

Not a recommendation — these are the questions worth bringing to the appointment:

1. Do I have a condition that matches one of the extra indications? Established cardiovascular disease points toward Wegovy; diagnosed moderate-to-severe OSA points toward Zepbound. This may also decide your insurance outcome.
2. What does my plan actually cover? Formularies frequently prefer one. That usually outranks everything else.
3. What is the 12-month cost of each, including membership, dose escalation and labs — not the first-month price.
4. Have I tolerated either before? Prior experience beats trial averages for you specifically.
5. What does my prescriber think, given my full history? Contraindications and other medications are their call, not a comparison table’s.

One thing worth saying plainly: the better trial result does not mean the better choice for you. A drug you can get, afford, and tolerate for two years will do more than one you stop after four months because of cost or side effects.

Educational content only. This is not medical advice, and nothing here should be used to choose or change a medication — that decision belongs with a licensed prescriber who knows your history.